How does maximizing shareholder value distort drug development? episode artwork

EPISODE · Jul 28, 2016 · 18 MIN

How does maximizing shareholder value distort drug development?

from Medicine and Science from The BMJ · host The BMJ

With the emergence of sofobuvir, a new direct acting antiviral, treatment for Hepatitis C infection is currently undergoing it's greatest change since the discovery of the virus 25 years ago. However Gilead, who manufacture the treatment, are under fire for the cost of the druge - around $90 000 for a course of treatment. Victor Roy, doctoral researcher at the University of Cambridge, discusses how the new drug was discovered and came to market, and what happened to the profits from sale. Read the full analysis: http://www.bmj.com/content/354/bmj.i3718

NOW PLAYING

How does maximizing shareholder value distort drug development?

0:00 18:01

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of Medicine and Science from The BMJ?

This episode is 18 minutes long.

When was this Medicine and Science from The BMJ episode published?

This episode was published on July 28, 2016.

What is this episode about?

With the emergence of sofobuvir, a new direct acting antiviral, treatment for Hepatitis C infection is currently undergoing it's greatest change since the discovery of the virus 25 years ago. However Gilead, who manufacture the treatment, are under...

Can I download this Medicine and Science from The BMJ episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!